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Anticoagulated patient’s perception of their
illness, their beliefs about the anticoagulant
therapy prescribed and the relationship
with adherence: impact of novel oral
anticoagulant therapy – study protocol for
The Switching Study: a prospective cohort
study
Vivian Auyeung2*, Jignesh P. Patel1,2, John K. Abdou1,2, Bipin Vadher1, Lynda Bonner1, Alison Brown1,
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Abstract
Background: Anticoagulant therapy is prescribed for millions of patients worldwide for the prevention and treatment
of both arterial and venous thrombosis. Historically, only vitamin K antagonists have been available for clinicians to
prescribe. The anticoagulation landscape is changing. The recent availability of the novel oral anticoagulants overcome
many of the disadvantages associated with vitamin K antagonists. However the lack of formal monitoring and clinic
follow-up is a concern for clinicians, as medication adherence is being assumed, which is known to decline in patients
prescribed medications for chronic conditions. The switching study is a programme of work investigating the association
between medication adherence and patient’s beliefs about anticoagulation therapy (warfarin and subsequently novel
oral anticoagulants), together with beliefs about their illness and anticoagulation related quality of life.
Methods/design: The anticoagulation database at King’s College Hospital will be interrogated and two groups of
patients will be identified; those with a time in therapeutic range on warfarin of ≥75 % and those <50 %. These
groups of patients will have their illness perceptions, anticoagulation specific quality of life and beliefs about
medications compared. Those patients in the time in therapeutic range <50 % group, will be then be invited to
switch to a novel oral anticoagulant, as per local guidance. Those patients, who do switch, will then be followed
longitudinally and have their adherence, illness perceptions, anticoagulation specific quality of life and beliefs
about medications, re-evaluated on the novel agent. The results from these sub-studies, will inform a clinical
pathway to support patients on these novel agents, which will be evaluated in an independent group of patients.
Discussion: The results from the switching study will be used to develop a clinical pathway to support patient’s
prescribed novel oral anticoagulant therapy long-term.
Keywords: Anticoagulants, Atrial fibrillation, Beliefs, Illness perceptions, Medication adherence, Venous
thromboembolism, Quality of life
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Background
Anticoagulant therapy is prescribed for millions of patient’s
world-wide, most commonly for the acute treatment and
long-term prevention of venous thromboembolism (VTE)
and as primary and secondary prevention of stroke in the
context of atrial fibrillation (AF) [1, 2]. Until recently the
majority of patients requiring chronic anticoagulant ther-
apy were prescribed vitamin K antagonists (VKA), as these
were the only oral anticoagulant agents available [1, 2].
VKA therapy comes with some practical disadvantages;
need for monitoring and a relatively significant number of
drug-drug and drug-food interactions, which has meant
that not all patients eligible have benefitted from these
agents in the past [3]. In recent years, the aforementioned
disadvantages has led to the development of new classes of
oral anticoagulants, the direct thrombin inhibitor (dabiga-
tran) and the direct Xa inhibitors (apixaban, betrixaban,
edoxaban, rivaroxaban). These agents hold many advan-
tages over VKA, primarily of a predictable pharmacoki-
netic nature, meaning that there is minimal requirement
for regular monitoring of anticoagulant effect [4]. In the
United Kingdom (UK), the available direct oral anticoagu-
lants, apixaban, dabigatran, edoxaban and rivaroxaban are
all approved for AF and VTE indications and available for
clinicians to prescribe as treatment options, when clinically
indicated [5–13]. Indeed their availability has sparked local
initiatives to ensure that patients in AF with a CHA2DS2-
VASc score [14] of two or above are offered oral anticoagu-
lation, be it with VKA or the novel agents, referred to
herein as NOAC. The general perception is, that the
NOACs are easier to use, so uptake both from a clinician
(prescribing) and patient (receiving) perspective is likely to
be higher, with cost analyses modelling suggesting that
these agents are cost-effective [5–13]. Treatment pathways
across the UK are being revisited to accommodate these
agents and the advantages they bring. However, these
agents are not free from risks. Compared to VKA, little ex-
perience exists on how these agents perform long-term,
e.g. in minimising complications associated with VTE such
as the post-thrombotic syndrome. Additionally, there are
currently no antidotes available for the direct Xa inhibitors;
a situation which is likely to change in the coming months.
Finally, the benefits cited for the NOACs assume that pa-
tients actually take the medication as prescribed. Research
suggests that approximately 30–50 % of medication pre-
scribed for chronic conditions are not taken as intended
[15]; adherence is often found to be high during the initial
months of therapy and then found to decline in many pa-
tients [16], with clinician’s ability to recognise medication
non-adherence reported to be poor [17–20]. Medication
non-adherence not only impacts negatively on the patient
concerned, the wider health-care economy is adversely
affected [21]. Research confirms that individual patient’s
beliefs about medicines are a strong predictor of their
adherence to treatment. These beliefs can be grouped
under two categories; (1) perceptions of necessity and (2)
concerns about negative effects [22]. Therefore beliefs that
failure to take the treatment could result in adverse conse-
quences is associated with higher adherence rates (and vice
versa). Acknowledging that all patients will have differing
beliefs about their medications is the first step in address-
ing the medication non-adherence problem [22, 23].
With the availability of NOAC therapy, an opportunity
now exists to re-visit patients who are currently pre-
scribed VKA with poor anticoagulation control, and
consider switching their anticoagulant therapy to a
NOAC. The question is how to determine success or
failure on VKA. A common method of determining
good anticoagulation control on VKA is through their
time in therapeutic range (TTR). The Rosendaal method
[24] is the most widely used method to calculate TTR
and uses linear interpolation to calculate an INR value
for each day between observed INR values (over a 1 year
period). The TTR represents the percentage of these
INR values in days that are in the therapeutic range. The
TTR is a valid marker to use in clinic, as it has been re-
ported to predict clinical outcomes such as major bleed-
ing, stroke and systemic embolic events [25]. TTR
provides a means, however imperfect [26], of identifying
possible medication non-adherence and/or whether the
patient may benefit from a switch to NOAC. In the UK,
national guidelines suggest using the TTR criteria for de-
termining which patients might be prioritised for switch-
ing to a NOAC. Indeed, the recently published National
Institute for Care Excellence guidelines for AF stipulate
that anticoagulation clinics should reassess anticoagula-
tion for patients with poor anticoagulation control, and
one of the criterion specified for re-assessment is if a
patient’s TTR is <65 % [27].
Non-adherence in the context of anticoagulant therapy
is not new and the issue has received attention from re-
searchers in the past [28–32], with the importance of
non-adherence to NOAC now emerging [33–35]. Little
research exists on what patients general and specific
concerns or necessity might be about the VKA that they
are currently prescribed. This is important, as with a sig-
nificant change in the anticoagulation landscape, under-
standing the patient perspective, particularly those with
poor TTR, could help identify patterns of concerns that
this group of patients may have, which could impact on
their medication taking behaviour, if switched to a NOAC.
Studying this would help with service delivery and deter-
mine if a specific clinical pathway would support adherence
with chronic anticoagulant therapy in those identified or
suspected of poor adherence - as currently, no long term
pathway for NOAC patients is expected to be in place.
The Switching study is a series of prospective studies
designed to investigate the association between medication
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adherence and patients’ beliefs about anticoagulation
therapy (warfarin and subsequently NOAC) together
with beliefs about their illness and anticoagulation-
related quality of life.
The Switching study aims to test the following
hypotheses:
Patients’ beliefs about warfarin and their illness
perceptions is associated with their adherence to
warfarin as measured by time in treatment range
(TTR), over and above any clinical or demographic
variables.
Patients’ beliefs about NOAC at baseline and their
illness perception can predict their adherence to NOAC,
over and above any clinical or demographic variables.
Patients with symptomatic disease (either VTE or AF)
have higher necessity scores for anticoagulant treatment
compared to patients with asymptomatic disease.
Patients with a TTR >75 % have low concerns and
higher necessity scores for warfarin than those with a
TTR <50 %.
Patient’s responses to the illness perception
questionnaire (IPQ) is specific to treatment and will
change, following a switch to NOAC.
Patient’s quality of life scores improve following a switch
to NOAC.
Methods/design
Patients and patient selection
Anticoagulated patients who meet the inclusion criteria,
defined by their TTR, will be identified through the
DAWN® databases used at King’s College Hospital NHS
Foundation Trust. King’s College Hospital is a large
teaching hospital, based in South East London, providing
specialist tertiary services of liver disease and transplant-
ation, neurosciences, haemato-oncology, cardiology and
foetal medicine. The anticoagulation service at King’s
is provided between two hospital sites; Denmark Hill
and Bromley. The combined anticoagulation popula-
tion is ~6, 000 patients, with a clinic average TTR of
76 and 73 % for the Denmark Hill and Bromley sites
respectively.
Patient selection for the studies will be dictated by
their current time TTR, as per protocol and whether pa-
tients fit the eligibility criteria. The anticoagulant clinic
at King’s utilises the DAWN® software, and the TTR is
calculated for patient’s prescribed chronic anticoagula-
tion, by reviewing INR values 1 year from the date of
calculation. The TTR calculation utilises the Rosendaal
method [24].
Psychometric instruments
The instruments which will be administered to patients
in this study comprise of the Beliefs about Medicines
Questionnaire (BMQ) [36], the revised Illness Perception
Questionnaire (IPQ-R) [37] and the Anti-Clot Treat-
ment Scale (ACTS) [38] quality of life instrument. The
BMQ is a validated instrument for assessing patient’s be-
liefs about medicines in general (overuse and harm) and
their prescribed medication specifically (necessity and
concerns). The IPQ-R is a validated instrument that as-
sesses patient’s perception of their illness. The measures
identity - the symptoms the patient associates with the
illness, cause - personal ideas about aetiology, time-line -
the perceived duration of the illness (chronicity) and
how it fluctuates (cyclical), consequences - expected ef-
fects and outcome and cure control - how one controls
or recovers from the illness (personal control) and the
treatments available to manage it (treatment control).
There is also a global measure of illness coherence – the
degree to which the illness makes sense to the patient
and emotional representation - a measure of the impact
of the illness on their emotional well-being. The ACTS
is a 17-item anticoagulation specific quality of life instru-
ment which measures burden (a 12-item scale) and bene-
fits (a 3 -item scale). The questionnaire packs administered
to patients in the Switching study are available as
Additional files 1, 2, 3 and 4 with this manuscript.
Switching study series
Study I
For study I, two groups of patients prescribed chronic
VKA for the primary and secondary prevention of stroke
in the context of AF and for treatment and secondary
prevention of VTE, will be recruited: those with a TTR
>75 % (group 1) and those with a TTR <50 % (group 2).
The TTR cut-off ’s of >75 and <50 % were chosen to in-
form groups 1 and 2, based on the availability of the
NOACs providing an opportunity to switch patients
poorly controlled on VKA; it was felt that the patients
with the poorest control should be given this option to
switch first, i.e. be prioritised. Furthermore, having two
distinct groups (<50 and >75 %) and understanding and
appreciating the differences between these two groups
will ensure that the hypotheses posed could be tested
and if appropriate, a suitable support mechanism can be
developed for patients prescribed chronic NOAC therapy
where it is anticipated that adherence might be an issue.
For group 1 patients, their illness perception for why
they are prescribed anticoagulant therapy, their beliefs
about VKA and their anticoagulation specific quality of
life explored through the aforementioned psychometric
instruments [36–38], once through the post. Eligible pa-
tients will be consecutively identified from the DAWN®
database. These patients will remain on VKA therapy,
due to their excellent TTR.
In contrast, group 2 patients, due to their poor TTR
will specifically be invited to clinic (visit 1) to have their
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beliefs about warfarin, their perception of their illness
and their quality of life explored through the aforemen-
tioned validated instruments. Study I will assess the as-
sociation between adherence to warfarin and i) patient
beliefs about treatment and ii) patient perception of their
illness and compare responses from group 1 and group
2 patients. In addition, a baseline level for patient’s
anticoagulation-specific quality of life will be established.
Study II
Following completion of the psychometric instruments,
patients in group 2 (from study I) will be asked if they
wish to switch to a NOAC, according to local guidelines.
Patients who then switch will prospectively be followed
in clinic will be required to return for a clinic visit at 1,
2 months and 1 year into NOAC treatment allowing for
the longitudinal assessment of adherence. At their 1-
month follow-up visit (visit 2), patients will be given a
questionnaire pack comprising of validated instruments
designed to assess their newly established beliefs about
NOAC therapy and any short-term changes in quality of
life. The same instruments will be administered at their
1-year follow-up (visit 4) to determine whether any
changes in beliefs, illness perceptions and quality of life
are sustained. The questionnaire pack will be posted to
the patient, prior to their clinic visit 4, requesting them
to complete and bring along to their clinic appointment.
To prevent participant burden, no questionnaires will be
administered at the 2-month follow-up visit (visit 3).
However, at 1-month and 2-month follow-up visits
(visits 2 and 3), patients will be asked to bring in their
NOAC medication to clinic, so a pill count can be con-
ducted by the reviewing clinician.
Patients identified in this group who decline a switch
to a novel agent, will also be followed longitudinally for
the duration of the study and any clinically relevant out-
comes will be reported. Furthermore, their reasons for
not wishing to switch, will formally be recorded and
described.
Analysis for studies I and II will be conducted on an
intention to treat basis.
Study III
Following completion of studies I and II, the data col-
lected will be analysed and used to design a clinical
pathway which will be evaluated in a third (independent)
group of patients (group 3 – patients with a TTR <50 %).
The clinical pathway will be informed from the 2-month
follow-up data collected up to visit 3 from patients in
group 2 of study II. Group 3 patients will have the same
follow-up in clinic as per the schedule outlined for group
2 patients, and analysis for study III will also be conducted
on an intention to treat basis. The findings from group 2
patients (beliefs about medicines, illness perceptions,
quality of life and adherence to anticoagulant therapy) will
then be compared to the findings from group 3 patients.
In this way, this controlled study design will then allow an
assessment of the effectiveness of the clinical pathway
developed. Figure 1 summarises the three studies which
form this programme of work.
Inclusion criteria
All patients with a TTR <50 % prescribed warfarin ther-
apy (for recruitment to group 2 and group 3). Where the
low TTR is not due recent hospital admissions, surgical
procedures or significant drug changes; this will be
determined, following initial identification of patients in
this group.
A control group will also be recruited comprising of
patients with a TTR >75 % (for recruitment to group 1).
Exclusion criteria
Patients with a TTR >50–<75 % (for recruitment to
group 2 and group 3).
Patients with a contra-indication to NOAC (i.e. abnormal
liver function tests, CrCl <15 ml/min, taking concurrent
interacting drugs which are contra-indicated).
Those patients unable to attend clinic for a formal
consultation.
Those patients unable to read English.
Those patients who do not wish to participate.
Pregnant patients.
Study outcomes
– Individual % medication adherence to direct acting
anticoagulant therapy (1 year following switch)
– Changes in patients beliefs about the anticoagulation
therapy prescribed, at 1 month and 1 year following
a switch to NOAC therapy
– Changes in patients illness perceptions (1 month
and 1 year following switch)
– Changes in patients anticoagulation specific quality
of life (1 month and 1 year following switch)
– Persistence with NOAC therapy, following a switch
from VKA (1 year following switch)
Data collection
Table 1 outlines the study visit schedule and what in-
struments will be administered when for study II, in-
cluding details of clinical information collected for
patients who consent to the study. For study III, a new
group of patients will be recruited, with the study visit
schedule also following the schedule outlined in Table 1.
For studies II and III, patients will be reviewed by
pharmacists trained in the field of anticoagulation work-
ing at King’s College Hospital. The questionnaire will be
administered by the pharmacist reviewing the patient in
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clinic, with patients offered the option of completing the
questionnaire in clinic or taking home and returning at
their subsequent clinic visit. Patients will be advised that
the questionnaires will take approximately 20 min to
complete.
Patients who are prescribed long-term anticoagulation
for the secondary prevention of VTE, and whose pri-
mary VTE event was a deep vein thrombosis, will at
each clinic visit, have an assessment of post-thrombotic
syndrome (PTS) using the Villalta score [39], as part of
their clinical review at clinic visits.
Adherence to NOAC
During the first 2 months of therapy, adherence to
NOAC will be recorded through a pill count at the 1
and 2 month follow-up visits (visits 2 and 3). This pill
count will be conducted by the pharmacist reviewing the
patient in clinic and will compare the number of tablets
the patient has to the number of tablets the patient is
expected to have, following the commencement of
NOAC. When patients are reviewed in clinic at 1 year
into their NOAC therapy, specific adherence screening
questions will be asked to assess adherence during
Fig. 1 Summary of the three sub-studies which form the Switching Study programme
Table 1 Schedule of visits for patients recruited to studies II and III
Visit 1 (baseline – on VKA) Visit 2 (1 month into NOAC) Visit 3 (2 months into NOAC) Visit 4 (1 year into NOAC)
Full medical and drug history obtained, including
calculation of aCHADS2 [44],
aCHA2DS2VASc [14],
HASBLED [45], the Medication Related Complexity
Index (MRCI) [46], SAMe-TT2R2 [26], the Charlson
index [47] and whether the patient has
symptomatic disease or not
Patient reviewed clinically Patient reviewed clinically IPQ/BMQ (NOAC)/ACTS
instruments administered
Socio-demographic informationb Patient self-reported missed
doses recorded + pill count
Patient self-reported missed
doses recorded + pill count
PTS assessment if DVT patient
Informed written consent Another 1 month prescription
of NOAC given to patient
Another 1 month prescription
of NOAC given to patient
Adherence assessment through
GP summary care record, patient
self-report and the 8-item Morisky
Medication Adherence ScaleIPQ/BMQ (warfarin)/ACTS instruments
administered
Bloods for UEs/FBC Bloods for UEs/FBC (if not
done at visit 2)
Patient switched to NOAC (1 month prescription) IPQ/BMQ (NOAC)/ACTS
instruments administered
Patient transferred to GP for
on-going prescriptions
PTS assessment if DVT patient PTS assessment if DVT patient PTS assessment if DVT patient
aonly for patients prescribed anticoagulant therapy in the context of atrial fibrillation
bsocio-demographic information will be obtained from the patient’s medical notes, namely age, gender, post-code, ethnicity
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months 4 to 12 of NOAC therapy [40] in addition to
asking patients how many doses of their anticoagulation
they have missed during the last week. The adherence
screening questions at this visit are informed from the
8-item Morisky Medication Adherence Scale [41]. Fur-
thermore, in order to assess persistence with their antic-
oagulation therapy, patient’s summary care record and
prescriptions records will be reviewed, allowing anticoa-
gulation coverage to be calculated, during the period
which the GP was prescribing the NOAC for the patient,
in order to measure persistence up to this time point.
Consent, confidentiality and data storage
Group 1 patients will be sent the study patient informa-
tion leaflet, along with the study questionnaire and a
pre-paid envelope, to return the completed question-
naire to the research team.
When group 2 patients are invited for the consultation
in the anticoagulation clinic, they will be sent the study
patient information and asked to read it prior to their
clinic visit. At the clinic visit, the pharmacist in clinic
will ask the patient if they wish to participate in the
study and address any questions they may have. For
those patients who indicate that they interested, the
pharmacist will recruit them into the study. Informed
written consent will be taken by the pharmacist. For
those patients who do not wish to participate, the
pharmacist will still offer the patient the opportunity to
switch to a NOAC, as per local guidance.
A similar process to that of group 2 patients will be
followed for group 3 patients, at the appropriate time for
study III.
All recruited patients will be reviewed in Haematology
outpatients at the respective hospitals, by pharmacists
trained in the study.
Data collected for the purposes of the study will be re-
corded by the pharmacist on a pre-determined study
form, which captures the information required for the
study. At the earliest opportunity, the principal re-
searcher associated with the study will transfer the data
to an excel database at the respective hospitals and sub-
sequently transfer to an SPSS database, with the hard
copy of the data collection form being filed and stored
in a locked office within the haematology department at
King’s College Hospital, with only members of the clin-
ical team having access to this office.
One week after entry of a patient’s data onto the SPSS
database, the data which had been entered will be re-
checked for any entry discrepancies by the principal
researcher.
As soon as a patient consents to participate in the
study, they will be given a unique study number. This
number will be entered onto the SPSS database and will
only be traceable back to an individual patient by accessing
the study form for the patient in the haematology depart-
ment at King’s College Hospital.
All electronic data will be encrypted and password
protected.
Only direct members of the research team will have
access to the full set of electronic data generated within
the study. The completed questionnaires for studies I, II
and III will be stored within a locked office within the
haematology department at King’s College Hospital.
Sample size and statistical analysis
Study I & II
Patients who are >75 % in TTR (group 1) will be classi-
fied as adherent and those who are <50 % in TTR (group
2) will be classified as non-adherent. To determine if pa-
tients’ beliefs about warfarin and their illness perception
is associated with their adherence status, univariate ana-
lyses will first be conducted to identify the key variables
that will be entered into the multiple logistic regression
model. Assuming a recruitment ratio of 1:1 of non-
adherent : adherent patients, a total sample size of 180
to 240 patients will be able to accommodate 6 to 8 pre-
dictive variables. i.e. up to 120 patients who are adherent
and up to 120 patients who are non-adherent are re-
quired as measured by TTR.
Multiple linear regression will be used to examine
whether illness and treatment beliefs can predict adher-
ence to NOAC. Using the formula that 15 observations
are needed per degree of freedom, a sample size of 240
will be able to test whether illness and treatment beliefs
(11 dimensions) and up to five demographic/clinical var-
iables can predict adherence to NOAC. Therefore a sam-
ple size of 240 patients who are switched to NOAC is
required.
However, as the refusal rate for switching to NOAC
for eligible patients is not known, and given that the
NOAC patient sample will derive from those who are
non-adherent to warfarin (<50 % TTR), at least 240 pa-
tients – rather than 120 patients - who are non-adherent
will need to be recruited in order to be able to perform
both the linear regression analysis and logistic regression
analysis. A conservative refusal rate of 30 % would sug-
gest 342 patients who are <50 % TTR on warfarin would
need to be recruited into group 2.
Study III
Three hundred forty-two patients will be recruited into
group 2 which will act as the control group. Power
calculations (GPower 3.1) assuming one-tailed analysis
using an independent groups design, suggest that a 1:1
matching i.e. recruiting 342 patients into the interven-
tion group (group 3) would allow for the detection of a
small-sized effect of the intervention (d = 0.20).
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The Switching study has been reviewed and given a fa-
vorable opinion by the London-Dulwich Research Ethics
Committee: REC reference: 13/LO/1468.
Discussion
The Switching study aims to understand patient’s per-
ception of their illness, their beliefs about medication
and their anticoagulation specific quality of life, as it
relates to adherence to anticoagulant therapy. We are
not the first to study this in a population anticoagulated
with VKA. Of particular note is the recently published
TREAT study [42, 43]. This study was a randomised
controlled trial of an intensive educational intervention
for patients requiring VKA for stroke prevention in the
context of AF. The study randomised warfarin-naïve
patients to usual care and the intervention or usual
care alone. The study administered the BMQ and IPQ-R
[36, 37] to patients at baseline, 1, 2, 6 and 12 months
post intervention, and found that a theory based edu-
cational intervention significantly improves TTR in
patients during the first 6 months, although these
benefits did not appear to be maintained longer-term.
This study demonstrates the utility of validated psy-
chometric instruments in understanding and designing
interventions that improve anticoagulation control in
patients, however the results also demonstrate that
more work is needed to understand techniques that
can support patients in maintaining effective levels of
self-management, particularly with the use of NOAC
therapy.
The availability of NOACs, has led to a drive in the
UK to ensure that patients who would benefit from oral
anticoagulation, are identified and offered appropriate
treatment; this is particularly the case for stroke preven-
tion in the context of AF. However, although these
agents are easier to use, both from a clinician and pa-
tient perspective, the lack of formal clinic follow-up and
re-enforcement of adherence could be a problem, given
what is already known about non-adherence to medica-
tion for chronic conditions. Current cost-analysis which
state that these NOAC are cost-effective [5–13], assume
full adherence to medication. This is clearly not a true
reflection of clinical practice. Therefore understanding
patients views about their illness, their beliefs about the
anticoagulant prescribed and their anticoagulation-
related quality of life, should help us to understand what
type of support patients prescribed both VKAs and
NOAC long-term might require to support adherence.
This should not only benefit the patient, it should help
ensure commissioners obtain value for money, given the
current and likely future financial constraints within the
health service.
Our study began recruitment in July 2014 and the full
results are expected in 3 years.
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